Ozempic (semaglutide) is a GLP-1 receptor agonist for treating type 2 diabetes and promoting weight loss. It lowers blood sugar by increasing insulin release and decreasing glucagon, slows digestion, and reduces appetite. Users can expect a 10-15% weight loss over a year. Common side effects include nausea and diarrhea. Considered for some with obesity or diabetes, it's not recommended for those with a history of certain cancers.